https://www.selleckchem.com/pr....oducts/asunaprevir.h
In this short review, we would like to summarize what is known today about ADDS for a wide readership of hematology clinicians in Japan. It is unclear whether there are differences in the clinical factors between atrial fibrillation (AF) recurrence and adverse clinical events (AEs), including stroke/transient ischemic attack (TIA), major bleeding, and death, after AF ablation.Methods and ResultsWe examined the data from a retrospective multicenter Japanese registry conducted at 24 cardiovascular centers between 2011 and 2017. Of the
Like
Comment
Share
